Genscript Biotech Corporation Cash Flow Conversion Efficiency

Latest as of June 2023: -0.045x

Genscript Biotech Corporation cash flow conversion efficiency. Based on the latest financial reports, Genscript Biotech Corporation (G51) has a cash flow conversion efficiency ratio of -0.045x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-93.58 Million ≈ $-109.41 Million USD) by net assets (€2.09 Billion ≈ $2.44 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Genscript Biotech Corporation (2016–2025)

Cash flow conversion efficiency of Genscript Biotech Corporation from 2016 to 2025. This chart illustrates how Genscript Biotech Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View G51 share price today for real-time trading data and today's change.

Genscript Biotech Corporation Cash Flow Conversion Ratio Explained

Genscript Biotech Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Genscript Biotech Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genscript Biotech Corporation ranked by their cash flow conversion efficiency. Also see Genscript Biotech Corporation (G51) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Impinj Inc NASDAQ:PI	0.072x
Sino-American Silicon Products TWO:5483	0.031x
National Storage Affiliates Trust NYSE:NSA	0.059x
Jason Furniture(Hangzhou) SHG:603816	0.071x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd SHG:600329	0.012x
Suzhou Everbright Photonics Co. Ltd. A SHG:688048	-0.001x
Skeena Resources Ltd TO:SKE	-0.084x
Jiangsu Changshu Rural Commercial Bank Co Ltd SHG:601128	-0.165x

Annual Cash Flow Conversion Efficiency for Genscript Biotech Corporation (2016–2025)

The table below shows the annual cash flow conversion efficiency of Genscript Biotech Corporation from 2016 to 2025. Review free cash flow generation of Genscript Biotech Corporation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€3.96 Billion ≈ $4.64 Billion	€325.52 Million ≈ $380.57 Million	0.082x	+369.25%
2024-12-31	€4.32 Billion ≈ $5.05 Billion	€75.65 Million ≈ $88.44 Million	0.017x	+112.47%
2023-12-31	€2.04 Billion ≈ $2.39 Billion	€-286.91 Million ≈ $-335.43 Million	-0.140x	-58.98%
2022-12-31	€1.36 Billion ≈ $1.59 Billion	€-120.29 Million ≈ $-140.63 Million	-0.088x	+29.47%
2021-12-31	€1.09 Billion ≈ $1.28 Billion	€-136.79 Million ≈ $-159.92 Million	-0.125x	+32.44%
2020-12-31	€815.59 Million ≈ $953.51 Million	€-151.09 Million ≈ $-176.64 Million	-0.185x	-130.25%
2019-12-31	€372.30 Million ≈ $435.26 Million	€-29.95 Million ≈ $-35.02 Million	-0.080x	-112.90%
2018-12-31	€493.30 Million ≈ $576.72 Million	€307.66 Million ≈ $359.69 Million	0.624x	+566.40%
2017-12-31	€228.32 Million ≈ $266.93 Million	€21.37 Million ≈ $24.98 Million	0.094x	-48.24%
2016-12-31	€184.02 Million ≈ $215.14 Million	€33.27 Million ≈ $38.90 Million	0.181x	--

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$10.11 Billion

€8.65 Billion EUR

Market Cap Rank

#4429 Global

#776 in Germany

Share Price

€3.96

Change (1 day)

-7.04%

52-Week Range

€1.14 - €5.45

All Time High

€5.45